Cheng, Alvan http://orcid.org/0000-0003-2281-1798
Deng, Xinqing
Yang, Fang
Liu, Cici
Neasham, David
Kilcoyne, Thomas
Duxbury, Michael
Cordey, Myriam
Elewski, Boni E.
Article History
Received: 15 December 2023
Accepted: 29 January 2024
First Online: 5 March 2024
Declarations
:
: Dr Cheng, Dr Cordey, and Dr Neasham reported being employees and stockholders of Amgen Inc. Ms Deng, Ms Yang, Ms Lue, Mr Kilcoyne, and Mr Duxbury reported being consultants for Amgen Inc. Dr Elewski reported receiving research funding from AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Celgene, Incyte, Leo, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, UCB, Sun Pharma, Valeant (Ortho Dermatologics), and Vanda, and has received honoraria from Amgen, Arcutis, Boehringer Ingelheim, BMS, Celgene, Leo, Lilly, Novartis, UCB, and Valeant (Ortho Dermatologics).
: As the data are de-identified and comply with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act of 1996, this study was exempt from ethics review.